This study tested the hypothesis that intensive treatment in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial disproportionately produced adverse outcomes in patients with diabetes with a high hemoglobin glycation index (HGI = observed HbA 1c 2 predicted HbA 1c ).
targeting HbA 1c levels of less than 6% (42 mmol/mol) would reduce the rate of cardiovascular events compared with a strategy targeting HbA 1c levels between 7.0% and 7.9% (53 and 63 mmol/mol). This hypothesis was not supported: Intensive treatment failed to improve primary cardiovascular outcomes and was instead associated with 22% greater total mortality compared with standard treatment. The ACCORD trial thus demonstrated that increased mortality was a previously unrecognized harm of intensive glucoselowering therapy in high-risk patients with type 2 diabetes. Although symptomatic severe hypoglycemia was associated with an increased risk of death in the intensive and standard treatment groups, differences in HbA 1c or rates of hypoglycemia between the two groups did not explain the greater mortality observed in the intensive-treatment group (2) .
Treating patients with diabetes with drugs that lower blood glucose levels inherently increases the risk for hypoglycemia. Intensively treating patients with diabetes to a low HbA 1c target implicitly assumes that all patients will have roughly the same blood glucose level when they reach the target. Miller et al. (3) paradoxically reported that ACCORD participants with higher HbA 1c levels had greater risk for hypoglycemia. If HbA 1c were an unbiased estimate of blood glucose, this observation would incongruously suggest that participants with higher blood glucose levels had greater risk for hypoglycemia. Numerous studies have shown, however, that some patients with diabetes have HbA 1c levels that are persistently lower or higher than predicted compared with other individuals with similar blood glucose levels (4) (5) (6) (7) (8) (9) (10) .
We reasoned that intensive treatment to a one-size-fits-all HbA 1c target of less than 6% (42 mmol/mol) may have inadvertently and disproportionately produced adverse outcomes in a subgroup of ACCORD patients with diabetes with lower blood glucose levels than their HbA 1c would predict. To test this hypothesis, we used the hemoglobin glycation index (HGI) to identify ACCORD participants with incongruous HbA 1c and FPG at baseline. HGI is the calculated difference between an individual's observed HbA 1c and a predicted HbA 1c derived by inserting the individual's blood glucose concentration into a population regression equation describing the linear relationship between HbA 1c and blood glucose (HGI = observed HbA 1c 2 predicted HbA 1c ) (4, 9) .
Assessment of HGI in the Diabetes Control and Complications Trial (DCCT) showed that patients with type 1 diabetes with a high HGI had a threefold greater risk for retinopathy and a sixfold greater risk for nephropathy (6) . Most prior HGI research calculated predicted HbA 1c based on mean blood glucose (self-monitored (4, 9) , timed profiles (6), or continuous glucose monitoring (11) ). HGIs calculated using all glucose data downloaded from patient meters were highly correlated with HGIs calculated using only prebreakfast glucose data (4) . The feasibility of using FPG to calculate the HGI in patients with type 2 diabetes was previously proposed (12) . The glycation gap developed by Cohen et al. (5) is calculated in exactly the same way as HGI except fructosamine replaces directly measured glucose for obtaining a predicted HbA 1c . Several studies have shown that patients with type 2 diabetes with a high glycation gap have greater risk for microvascular or macrovascular complications (5, 10, 13, 14) . HGI and the glycation gap are strongly positively correlated, which suggests they reflect the same biological phenomenon (15) .
Patients with diabetes with low and high HGI have HbA 1c levels that are lower or higher than predicted, respectively, compared with other patients with similar blood glucose levels. We hypothesized that intensive treatment produced disproportionately lower blood glucose levels and increased hypoglycemia in the subgroup of ACCORD participants with a high HGI. This could explain the otherwise paradoxical results reported by Miller et al. (3) . Also, higher baseline HbA 1c and higher average on-treatment HbA 1c were both strong predictors of mortality associated with intensive treatment in ACCORD (16, 17) . Because HGI was associated with increased complications risk in patients with type 1 diabetes in the DCCT, we also hypothesized that patients with type 2 diabetes with high HGI in ACCORD might also have a greater risk for primary cardiovascular outcomes, total mortality, and microvascular disease.
RESEARCH DESIGN AND METHODS
This research was approved by the institutional review boards at the Louisiana State University Health Sciences Center and Children's Hospital, New Orleans, LA.
ACCORD Study Design
ACCORD was a multicenter, randomized clinical trial that used a double 2 3 2 factorial design to incorporate intervention trials for glycemia, hyperlipidemia, and hypertension. The lipid intervention trial tested in 5,518 participants the hypothesis that a hypolipidemic agent would improve outcomes in subjects with good glycemic control. The blood pressure intervention trial tested in the remaining 4,733 participants the hypothesis that a therapeutic strategy that targets a systolic blood pressure of ,120 mmHg will reduce the rate of CVD events compared with a strategy that targets a systolic blood pressure of ,140 mmHg. All participants enrolled in the ACCORD trial had type 2 diabetes and had experienced a prior cardiovascular event or had other evidence of high risk for CVD. Median follow-up time was 5.0 years (mean 5.0; range 0.01-8.4). The rationale, study design, inclusion criteria, and other details of the ACCORD trial are described elsewhere (1, (18) (19) (20) .
The glycemia intervention trial included all 10,251 ACCORD participants, who were randomly assigned at baseline to a standard treatment group or an intensive treatment group. Any antihyperglycemic agent or combination of agents approved by regulatory authorities could be used as considered appropriate to achieve protocol-mandated target HbA 1c levels of 7.0% to 7.9% (53 to 63 mmol/mol) in the standard treatment group, or less than 6.0% (42 mmol/mol) in the intensive treatment group. During the trial, excess mortality was demonstrated at 3.5 years of average follow-up, at which time all participants in the intensive treatment group were converted to the standard treatment regimen (20) . Data for this ancillary study were obtained from the ACCORD coordinating center on all enrolled participants. Only data from participants with FPG and HbA 1c recorded at baseline (n = 10,125) were used in these analyses.
Primary and Secondary Outcomes
The prespecified primary outcome for ACCORD was a composite of the first occurrence of nonfatal myocardial infarction (MI), nonfatal stroke, or death from cardiovascular causes (18) . Causes of cardiovascular death included fatal MI, congestive heart failure, documented arrhythmia, death after invasive cardiovascular interventions, death after noncardiovascular surgery, fatal stroke, unexpected death due to ischemic CVD occurring less than 24 h after the onset of symptoms, and death due to other vascular diseases such as pulmonary emboli or abdominal aortic aneurysm rupture. Death from any cause was one of several prespecified secondary outcomes (1) . Primary and secondary outcomes were assessed from baseline through the last set of scheduled study visits (March-June 2009) (20) .
Definition of Severe Hypoglycemia
Symptomatic, severe hypoglycemia requiring any assistance was defined as an episode of hypoglycemia with a documented blood glucose concentration of less than 50 mg/dL (2.8 mmol/L) in which the participant reported receiving medical care or assistance from another individual or recovery with carbohydrate treatment. Symptomatic, severe hypoglycemia requiring medical assistance was defined as an episode of hypoglycemia in which the participant received care at a hospital or emergency department or from medical personnel. Hypoglycemia assessment included hypoglycemia events from baseline up to the transition period when intensive glycemic intervention was terminated (February 2008). . The use of a tertile classification system is by convention for consistency with previous HGI studies. We compared HGI classifications using simple linear regression with HGI classifications based on cubic spline regression and observed more than 90% identity. We chose the linear regression model because this approach is simpler and has precedent.
Statistical Analysis
Baseline characteristics and other variables were compared among low, moderate, and high HGI subgroups. Group comparisons used ANOVA or KruskalWallis tests for normally distributed and nonnormally distributed continuous variables, respectively, and x 2 tests were used for categorical variables. KaplanMeier curves and log-rank tests were used to compare the distribution of time to first event. Post hoc analyses were performed to compare risk of primary outcomes, total mortality, and hypoglycemia between the intensive and standard glycemia treatment groups and among HGI subgroups with adjustment for covariates. Hazard ratios and 95% CI were determined by stratified Cox proportional hazards regression models. Tests of statistical significance were based on a two-tailed type 1 error at P , 0.05. The interaction term of HGI subgroup with glycemia treatment was added to each model, and a likelihood ratio test was applied. Whenever the interaction test did not meet the criteria for statistical significance, a Bonferroni correction for multiple comparisons was applied when evaluating the effect of treatment by subgroup. Proportional hazards assumptions were assessed by cumulative sums martingale residuals over follow-up times using Kolmogorov-type supremum tests and no violation was found.
Covariates included baseline characteristics, study location among the seven clinical-center networks, and for other ACCORD intervention assignments (the blood pressure trial, assignment to the intensive blood pressure intervention group, or the lipid trial, assignment to receive fibrate in the lipid trial). Sensitivity analyses were performed to determine hazard ratio stability after including intervention assignments in the Cox model as stratifying factors rather than as covariates. Baseline characteristics were age, sex, ethnicity, education level, medical history (smoking history, duration of diabetes, retinopathy detected at baseline, history of CVD, high risk of congestive heart failure, evidence of significant atherosclerosis, albuminuria), and laboratory and clinical measures at baseline (FPG, diastolic blood pressure, estimated glomerular filtration rate, LDL-cholesterol, HDL-cholesterol, and triglycerides). Outcomes based on Cox regression models were similar to those obtained using logistic regression. We used Cox regression in reporting our results to account for the fact that ACCORD participants were monitored for different lengths of time, leading to a changing denominator over time that is not adequately modeled by the constant average denominator imposed by the logistic model. Statistical analyses were performed using SAS 9.3 or STATA 13 software. Figure 1C shows the linear relationship between HbA 1c and FPG in the ACCORD population at baseline. Figure 1A and B shows that the frequency distribution of HbA 1c was markedly different in the low, moderate, and high HGI subgroups. In contrast, FPG distribution was similar among the subgroups. Selected baseline demographic, biochemical, and clinical characteristics are compared among the HGI subgroups in Table 1 . Of particular note, there were disproportionately more black and Hispanic participants and fewer white participants in the high HGI subgroup. Furthermore, high HGI participants were younger, had longer duration of diabetes, were more likely to already have retinopathy and a history of albuminuria at baseline, and were more likely to have used insulin before the start of the study. After 1 year of standard ( Fig. 2A) or intensive (Fig. 2B ) treatment, mean HbA 1c remained significantly different (P , 0.001) between HGI subgroups and was highest in the high HGI subgroup. In contrast, the mean FPG was significantly lower (P , 0.001) in the moderate and high HGI subgroups after 1 year of standard treatment ( Fig. 2A) and was not different (P . 0.05) between HGI subgroups after 1 year of intensive treatment (Fig. 2B) . The number of participants above or below the HbA 1c intensification thresholds varied after 1 year in the standard treatment arm: 43.0% of high HGI participants remained above the 8% (64 mmol/mol) intensification threshold compared with only 30.6% of moderate and 21.9% of low HGI participants. After 1 year in the intensive treatment arm, 88.7% of high HGI participants remained above the 6% (42 mmol/mol) intensification threshold compared with 83.9% of moderate and 72.7% of low HGI participants. Barring mitigating circumstances, such as a recent hypoglycemic event, having disproportionately more participants above the intensification threshold should have resulted in greater treatment intensification at the 1-year visit.
RESULTS
Kaplan-Meier (Fig. 3) and Cox regression analyses (Table 2) show that the effect of intensive treatment differed markedly among the HGI subgroups. For example, if we ignore HGI, the event rate for primary outcomes was not significantly different (P = 0.09) between the intensive (9.8%) and standard (10.7%) treatment groups ( Table 2 and Fig. 3A) . A statistically significant interaction was detected between treatment and HGI (P = 0.0091). Subsequent HGI subgroup analysis showed that intensive treatment reduced primary outcomes by 25% (P = 0.02) in the low HGI subgroup and by 23% (P = 0.02) in the moderate HGI subgroup (Table 2 and Fig. 3B ). In contrast, primary outcomes in the high HGI subgroup were not significantly different between the standard and intensive glycemia treatment groups (P = 0.20).
Ignoring HGI again, total mortality (Table 2 and Fig. 3C ) was significantly greater (P = 0.02) in the intensive treatment group (7.7%) compared with the standard treatment group (6.3%). There was no interaction between treatment and HGI (P = 0.22). HGI subgroup analysis showed that although intensive treatment significantly increased total mortality by 41% (P = 0.02) in the high HGI subgroup, it had no effect on mortality in the moderate or low HGI subgroups compared with standard treatment (Table 2 and Fig. 3D ). Ignoring HGI once more, hypoglycemia requiring any assistance was more than threefold greater (P , 0.001) in the intensive treatment group compared with the standard treatment group (Table 2 and Fig. 3E ). HGI subgroup analysis showed that the incidence of hypoglycemia was progressively higher in the low, moderate, and high HGI subgroups in the intensive (14.5, 16.8, and 18.8%, respectively) and standard (3.7, 4.5, and 7.5%, respectively) glycemia treatment groups (Table 2 and Fig. 3F ). Results were similar for hypoglycemia requiring medical assistance. Sensitivity analyses that included other intervention assignments as stratifying factors in the Cox models, rather than as covariates, showed that the estimated HRs for primary outcomes, total mortality, and hypoglycemia remained stable.
CONCLUSIONS
Interindividual variation in HbA 1c caused by factors other than blood glucose concentration appears to be partly hereditary (21, 22) and has been reported in patients with type 1 diabetes (4-9,23,24), with type 2 diabetes (12) (13) (14) (25) (26) (27) , and without diabetes (28) (29) (30) (31) (32) . Pediatric patients with type 1 diabetes with higher HGI had higher levels of skin advanced glycation end products (33) . HbA 1c levels that are persistently lower or higher than expected among individuals with similar blood glucose levels have been detected in studies where blood glucose was estimated based on FPG (12), selfmonitored mean blood glucose (4,8,9,34), 7-point mean blood glucose profile sets (6, 35) , continuous glucose monitoring (7, 11) , or fructosamine (5, 26, 27) . Unlike other methods for estimating blood glucose, continuous glucose monitoring and fructosamine are relatively free of sampling bias yet produce similar results when assessing interindividual variation in HbA 1c .
The present studies indicate that subjects in ACCORD with high HGIs had more retinopathy and nephropathy at baseline, as previously reported in the DCCT (6). The differences in drug use observed between HGI subgroups at baseline could be related to the fact that insulin is more likely to be prescribed for individuals with persistently higher HbA 1c (high HGI). Alternatively, different drugs have been shown to influence the quantitative relationship between HbA 1c and blood glucose concentration (36) , which could in turn influence the HGI. Higher HGI among black ACCORD participants supports our previous observation of racial variation in HGI in children with type 1 diabetes (8). Evidence of clinically significant interindividual variation in the quantitative relationship between blood glucose concentration and HbA 1c markedly complicates the use of HbA 1c for the diagnosis and management of diabetes, especially in mixed-race populations (37) (38) (39) (40) (41) (42) .
Heterogeneity of Treatment Outcomes Among HGI Subgroups in ACCORD
Our present analyses examine the ACCORD glycemia trial through a new lens, namely, the HGI calculated using FPG and HbA 1c measured at baseline. As previously reported by the ACCORD investigators, we observed no difference in primary outcomes between the standard and intensive treatment groups despite our use of a slightly different data set (we omitted patients without HbA 1c or FPG at baseline) and different statistical methods. HGI subgroup analysis indicated, however, that intensive treatment actually improved primary outcomes in low and moderate HGI participants, a beneficial effect that was offset and masked by the apparently detrimental effects of intensive treatment in the high HGI subgroup. Although total mortality was significantly higher in the intensive treatment group, HGI subgroup analysis showed that the higher mortality associated with intensive treatment was restricted to the high HGI subgroup. Collectively, these observations show that HGI identifies two subpopulations in ACCORD, one that experiences benefits and one that experiences harms from the same intensive glucose-lowering strategy.
The risk for hypoglycemia was greatest in the high HGI subgroup in the standard and intensive treatment groups. More high HGI participants remained above the protocol-mandated HbA 1c treatment thresholds after 1 year of standard or intensive treatment. Despite higher mean HbA 1c , high HGI participants in both glycemia treatment groups had mean FPG values after 1 year that were as low as or lower than those observed in low HGI participants. Collectively, these observations are consistent with our hypothesis that intensive treatment may have inadvertently caused high HGI participants to receive more intensive treatment and could explain the otherwise paradoxical results reported by Miller et al. (3) .
Clinical Implications
The twin goals of diabetes management are to keep blood glucose levels low enough to limit the development of long-term diabetes complications but high enough to avoid hypoglycemia. After the ACCORD trial reported that intensive treatment increased mortality and hypoglycemia, the American Diabetes Association (ADA) recommended that HbA 1c treatment goals for individual patients should be personalized according to characteristics such as age and frequency of hypoglycemia, while also reiterating that lowering HbA 1c generally helps prevent or delay long-term complications (43). Our observations of markedly different outcomes in the different HGI subgroups in response to intensive treatment strongly supports the ADA recommendation for more personalized diabetes management and suggests that HGI could be used to help individualize treatment goals.
Exactly how the results of this study might be used to reinterpret other clinical trials or how the results might be applied in future trial designs or in clinical practice remains to be determined. One reason is that ACCORD participants were older than the general public and selected for elevated risk for CVD. This could explain why the baseline regression equation in ACCORD is markedly different from the linear regression equations reported by studies such as the A1C-Derived Average Glucose (ADAG) study (44). As such, the results may not be generalizable to other clinical trials or to the general population with diabetes and we cannot recommend the use of the ACCORD regression equation in other populations. Furthermore, only one other study has used FPG to assess the HGI in patients with type 2 diabetes, and these results were only reported in a meeting abstract (12) . All other prior HGI and glycation gap studies in patients with diabetes used some estimate of mean blood glucose or fructosamine. Additional studies of HGI in other clinical trials could help determine how best to use the HGI in clinical practice.
Conclusion
Intensive treatment to a low HbA 1c target of less than 6% (42 mmol/mol) cannot be recommended for all patients with type 2 diabetes because primary cardiovascular outcomes, total mortality, and hypoglycemia were all adversely affected in high HGI participants in ACCORD. Further studies should determine if the observed beneficial effects of intensive treatment on primary outcomes in low and moderate HGI participants outweigh any detrimental effects that might be caused by the increase in hypoglycemia associated with intensive treatment. Our results confirm that HbA 1c is not a one-size-fits-all indicator of blood glucose concentration and suggest that failure to take this into account can result in suboptimal diabetes care.
